SIBN Working Capital Per Revenue	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Working Capital Change	-1.55 %	-3.99 %	-6.64 %	-7.19 %	62.76 %
Y / Y Revenue Change	23.32 %	28.45 %	17.46 %	19.97 %	15.77 %
Working Capital Per Revenue	1.03	1.09	1.18	1.25	1.33
Working Capital Per Revenue Ranking	# 2086	# 1639	# 2509	# 1836	# 2251
Seq. Working Capital Change	-0.25 %	0.87 %	-0.79 %	-1.38 %	-2.72 %
Seq. Revenue Change	-6.19 %	24.75 %	0.83 %	4.52 %	-2.29 %

New: More SIBN's historic Working Capital Per Revenue Ratios >>

See SIBN Capital expenditures by quarter >> Back to SIBN Financial Strength Comparisons >> See SIBN Balance Sheets

Comment on SIBN's Working Capital Per Revenue in the first quarter 2025

Si Bone Inc 's Working Capital Per Revenue in the Q1 2025 sequentially fell to 1.03 below the company average.

Within Healthcare sector 34 other companies have achieved lower Working Capital Per Revenue during the Q1 2025. While Working Capital Per Revenue total ranking has deteriorated in the first quarter 2025, compared to previous quarter from 1639 to 2086.

Working Capital Per Revenue Ranking
Within:	No.
Industry	# 6
Sector	# 35
S&P 500	# 2086

Working Capital Per Revenue Statistics
High	Average	Low
3.86	1.72	1.02
(Jun 30 2020)		(Mar 31 2025)

Financial Statements
Si Bone Inc 's Working Capital	$ 181 Millions	Visit SIBN's Balance sheet
Si Bone Inc 's Revenues	$ 47 Millions	Visit SIBN's Income Statement
Where are SIBN's Sales coming from?		Visit SIBN's Sales by Geography

Companies with similar Average Working Capital Per Revenue for 12 months ending Mar 31 2025, within Healthcare Sector	Working Capital Per Revenue
Harvard Apparatus Regenerative Technology Inc	2.82
Zymeworks Inc	2.79
Madrigal Pharmaceuticals Inc	2.79
Xoma Royalty Corporation	2.77
Day One Biopharmaceuticals Inc	2.75
Zomedica Corp	2.73
Dynavax Technologies Corporation	2.71
Utah Medical Products Inc	2.60
Femasys Inc	2.57
Urogen Pharma Ltd	2.55
Protagonist Therapeutics inc	2.50
Quanterix Corporation	2.37
Mersana Therapeutics inc	2.36
Nektar Therapeutics	2.34
Ionis Pharmaceuticals Inc	2.33
Verrica Pharmaceuticals Inc	2.32
Keros Therapeutics Inc	2.32
Entrada Therapeutics Inc	2.30
Rapid Micro Biosystems Inc	2.29
Immunocore Holdings Plc	2.27
Gossamer Bio Inc	2.23
Ginkgo Bioworks Holdings Inc	2.22
Xenetic Biosciences Inc	2.22
Marker Therapeutics inc	2.20
Dyadic International Inc	2.14
Humacyte Inc	2.10
Outset Medical Inc	2.06
Amarin Corp Plcuk	2.04
Cvrx inc	2.04
Moderna Inc	2.03

Date modified: 2025-05-07T13:38:32+00:00

Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com